Business
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as pa
About this update from Sera Prognostics, Inc.
[{"type":"text","content":"SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same effort, he will not stand for re-election at the end of his term at the Company's 2025 Annual Meeting of Stockholders.","length":833,"tagName":"p"},{"type":"image","alt":"Jeff Elliott","displaySize":"","headline":null,"caption":"Jeff Elliott","className":"","disableSlideshowImg":false,"size":{"original":{"width":286,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/f63f5a458fa6a9b62751172a3cde9f26"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8Y.KZ7JWBX9F4znHAY9sEQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU4NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f63f5a458fa6a9b62751172a3cde9f26","width":286,"height":400}},"href":"https://mma.prnewswire.com/media/2645626/Sera_Prognostics_Jeff_Elliott_headshot.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are very excited for Jeff to join Sera and to make a talented board even deeper with his breadth and depth of expertise in commercially scaling companies in our sector," said Zhenya Lindgardt, President and CEO of Sera Prognostics. "He brings extensive experience in corporate strategy, business operations, analytics, public company finance, and commercializing molecular diagnostics. Jeff's unique background in growing diagnostics businesses will be helpful to Sera as we begin leveraging our recent PRIME results into active market building for our PreTRM® test. We are grateful to Ryan Trimble for his strong strategic direction and steady hand in bringing Sera to where we are today. And we thank Marcus Wilson for his invaluable contributions to the Company, including his central role in the recently completed PRIME study...